Neville Rodie & Shaw’s Acceleron Pharma XLRN Stock Holding History

Neville Rodie & Shaw’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-22,964	Closed	-$3.95M	–	269
2021 Q3	$3.95M	Hold	22,964	–	–	0.31%	65
2021 Q2	$2.88M	Hold	22,964	–	–	0.22%	80
2021 Q1	$3.11M	Hold	22,964	–	–	0.26%	75
2020 Q4	$2.94M	Hold	22,964	–	–	0.25%	72
2020 Q3	$2.58M	Hold	22,964	–	–	0.24%	74
2020 Q2	$2.19M	Hold	22,964	–	–	0.23%	80
2020 Q1	$2.06M	Hold	22,964	–	–	0.25%	81
2019 Q4	$1.22M	Sell	22,964 -10,000	-30%	-$456K	0.12%	118
2019 Q3	$1.3M	Sell	32,964 -10,000	-23%	-$434K	0.14%	111
2019 Q2	$1.76M	Hold	42,964	–	–	0.19%	101
2019 Q1	$2M	Hold	42,964	–	–	0.21%	93
2018 Q4	$1.87M	Hold	42,964	–	–	0.23%	91
2018 Q3	$2.46M	Hold	42,964	–	–	0.24%	94
2018 Q2	$2.08M	Buy	+42,964	New	+$1.57M	0.22%	97

Neville Rodie & Shaw's XLRN Position: Q4 2021 in Review

Neville Rodie & Shaw sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 22,964 shares — an estimated $3.95M sold.

Neville Rodie & Shaw first reported a position in XLRN in Q2 2018 and held it in 14 quarters. The position peaked at $3.95M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Neville Rodie & Shaw reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Neville Rodie & Shaw sold 22,964 Acceleron Pharma shares in Q4 2021, an estimated $3.95M.
Neville Rodie & Shaw first reported a position in Acceleron Pharma in Q2 2018 and held it in 14 quarters.
Neville Rodie & Shaw's Acceleron Pharma position peaked at $3.95M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Neville Rodie & Shaw's 13F filing for Q4 2021, filed 5 Jan 2022.